Cassava Sciences Inc (SAVA) stock plummeted 5.47% in pre-market trading on Tuesday, following an analyst downgrade by H.C. Wainwright.
H.C. Wainwright analyst Vernon Bernardino lowered the rating on Cassava Sciences from Buy to Neutral, removing the price target on the stock. The downgrade came after the company announced a disappointing development related to its Alzheimer's drug candidate.
The analyst action weighed heavily on investor sentiment, triggering a selloff in Cassava Sciences shares during the pre-market session. The stock's plunge erased a significant portion of the gains it had accumulated over the past few trading sessions.
Comments